Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 8/20 | 0.67 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.50 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.47 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.47 |
| ▸ | BCHE | P06276 | 2/20 | 0.46 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | CNR2 | P34972 | 1/20 | 0.46 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.44 |
| ▸ | HTR2C | P28335 | 1/20 | 0.43 |
| ▸ | HTR2B | P41595 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4262549 | 0.81 | EPHX2 (0.86) | EPHX2P2RX7FAAHCNR2 | |
| SCHEMBL4259208 | 0.81 | EPHX2 (0.60) | EPHX2P2RX7FFAR1FFAR4FAAH | |
| SCHEMBL4257643 | 0.80 | EPHX2 (1.00) | EPHX2P2RX7FAAHCNR2EPHX1 | |
| SCHEMBL4882859 | 0.80 | EPHX2 (0.66) | EPHX2FFAR1FFAR4BCHEFAAH | |
| SCHEMBL9668580 | 0.77 | EPHX2 (0.62) | EPHX2FFAR1FFAR4BCHEEPHX1 | |
| SCHEMBL1437584 | 0.76 | FFAR1 (0.65) | EPHX2FFAR1FFAR4BCHE | |
| SCHEMBL4257641 | 0.75 | EPHX2 (0.68) | EPHX2P2RX7FAAHCNR2 | |
| SCHEMBL2747433 | 0.74 | EPHX2 (0.46) | EPHX2 | |
| SCHEMBL14086742 | 0.73 | EPHX2 (1.00) | EPHX2P2RX7FAAHCNR2 | |
| SCHEMBL4882846 | 0.73 | EPHX2 (0.74) | EPHX2P2RX7FFAR1FFAR4BCHE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | ARETE THERAPEUTICS, INC. | 2009-01-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090023731-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885P2RX7 623/4885FFAR1 617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.